Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in respiratory virus vaccine development.

Alexander C Schmidt1

  • 1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-8007, USA. schmidta@niaid.nih.gov

Seminars in Respiratory and Critical Care Medicine
|April 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design.

Vaccine·2026
Same author

Impact of <i>Bifidobacterium infantis</i> supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan.

Frontiers in nutrition·2026
Same author

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.

Vaccine·2026
Same author

BCG Revaccination to Prevent Tuberculosis. Reply.

The New England journal of medicine·2025
Same author

Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01<sub>E-4</sub> in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial.

The lancet. HIV·2025
Same author

BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> Infection.

The New England journal of medicine·2025
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Developing new vaccines for viral respiratory infections in children and adults is crucial. Advances in reverse genetics are accelerating the creation of novel vaccines for viruses like RSV and influenza.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Viral respiratory infections pose significant health risks, especially to infants, young children, and the elderly.
  • Current vaccine development efforts are focused on pathogens causing severe lower respiratory disease.

Purpose of the Study:

  • To review the progress in developing novel vaccines against critical respiratory viruses.
  • To highlight the importance of reverse genetics in rational vaccine design.

Main Methods:

  • Review of current literature on respiratory virus vaccine development.
  • Discussion of reverse genetics technologies and their application.
  • Analysis of preclinical and clinical progress for various viral vaccines.

Main Results:

Related Experiment Videos

  • Influenza virus vaccines are established, but vaccines for RSV, metapneumovirus, parainfluenza, and pandemic influenza viruses are still needed.
  • Reverse genetics systems are instrumental in advancing vaccine development.
  • Significant progress has been observed in preclinical and clinical trials for new respiratory virus vaccines.

Conclusions:

  • Novel vaccines are essential to combat the burden of viral respiratory infections.
  • Continued research and development, particularly utilizing reverse genetics, are key to future vaccine availability.